Clinical trial · Interventional
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573CI-TRIAL-00085650EVOLITIONrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients receiving first line of treatment with a RCHOP 21 regimen
- description
- All patients will receive first line of treatment with a RCHOP 21 regimen
- interventionNames
- Biological: blood sampling
Primary outcomes (1)
- measure
- Prospective quantitative analysis of the level of circulating nucleosomes at baseline and during treatment in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
- timeFrame
- From enrollment to the end of the study (24 months of follow-up from beginning of treatment for each patient)
Secondary outcomes (2)
- measure
- Correlation between the level of circulating nucleosomes (number of cells) and the response to treatment as defined by international response criteria
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen * Agreement to participate after receiving oral and written information on the study Exclusion Criteria: * History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma) * Treatment with a chemotherapy regimen different from RCHOP21
References
Publications (0)
Data not yet available
No reference posted for this study.